ClinicalTrials.gg
CompletedNCT00143273JADEUpdated Aug 10, 2011

Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation

A Phase 2 interventional study of lasofoxifene and Placebo in Osteoporosis, sponsored by Ligand Pharmaceuticals. Completed at 17 sites in 3 countries. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-08-10.

Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
497
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Osteoporosis with a site in Japan — 7 open to participants now, 7 under way, none of them phase 3. Osteoporosis · Japan.

Enrollment
9th of 29
497 · median 170
Started
2004
with 1 other
Phase 2
9 of 42
4 open now
Registered
2nd of 42
by date
Lead sponsor
2 of 42
Ligand Pharmaceuticals

Among the 42 studies in Osteoporosis with a site in Japan, this one is the 9th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2004, is one of 9 in phase 2, and was the 2nd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

7 of the 42 studies in Osteoporosis with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 40 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Osteoporosis with a site in Japan, or all of them as a file.
02

Study summary

To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asian women with osteoporosis defined by low BMD

Exclusion criteria

Exclusion Criteria:

  • Metabolic bone disease, use of other osteoporosis drugs or drugs interering with normal bone metabolism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
497 participants (actual)

Study arms

  • Experimental
    Lasofoxifene Dose 1

    0.05 mg

    Drug: lasofoxifene

  • Experimental
    Lasofoxifene Dose 2

    0.25 mg

    Drug: Lasofoxifene

  • Experimental
    Lasofoxifene Dose 3

    0.5 mg

    Drug: Lasofoxifene

  • Placebo comparator
    Placebo

    0 mg

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Effects of lasofoxifene compared to placebo on Bone Mineral Density (BMD) changes at the spine and hip after 1 year of treatment

    Percent change from baseline in lumbar spine BMD at Month 12

    Time frame: 12 months

Secondary outcomes

  1. Hip BMD, bone markers, lipids and new radiographic vertebral fractures at 1 year

    Percent change from baseline in lumbar spine BMD at Month 6, percent change in baseline in hip BMD at Month 6 and Month 12, percent change from baseline in bone metabolism markers at Month 6 and Month 12, percent change from baseline in serum lipids, total cholesterol, high-density lipoprotein cholesterol, triglycerides, lipoprotein (a), apoliporpotein-A1, apolipoprotein-B at Month 6 and Month 12 and incidence of new vertebral fractures at Month 12

    Time frame: Month 6 and Month 12

07

Study locations

17 sites
  • Pfizer Investigational Site
    Fukuoka-shi, Fukuoka 810-0021, Japan
  • Pfizer Investigational Site
    Kagoshima-shi, Kagoshima 892-0824, Japan
  • Pfizer Investigational Site
    Kagoshima-shi, Kagoshima 892-0845, Japan
  • Pfizer Investigational Site
    Miyazaki-shi, Miyazaki 880-0052, Japan
  • Pfizer Investigational Site
    Fuchu, Tokyo 183-0051, Japan
  • Pfizer Investigational Site
    Kiyose, Tokyo 204-0021, Japan
  • Pfizer Investigational Site
    Minato-ku, Tokyo 106-0032, Japan
  • Pfizer Investigational Site
    Minato-ku, Tokyo 108-0075, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo 157-0066, Japan
  • Pfizer Investigational Site
    Yonago-shi, Tottori 683-8504, Japan
  • Pfizer Investigational Site
    Kangnam-ku, Seoul 135-710, Korea, Republic of
  • Pfizer Investigational Site
    Sonpagu, Seoul 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Youngdeungpo-gu, Seoul 150-713, Korea, Republic of
  • Pfizer Investigational Site
    Changhua City 500, Taiwan
  • Pfizer Investigational Site
    Taipei, 100, Taiwan
  • Pfizer Investigational Site
    Taoyun 333, Taiwan
  • Pfizer Investigational Site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 2, 2005
Start
Jun 2004
Primary completionActual
Mar 2006
CompletionActual
Mar 2006
Last update
Aug 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00143273
First posted
Sep 2, 2005
Start date
Jun 2004
Primary completion
Mar 2006
Completion
Mar 2006
Last update
Aug 10, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasofoxifene

Start the discussion